SolasCure has raised 拢15 million Series A investment to support the development of its wound cleaning product, Aurase.
The Cambridge-based MedTech company has been backed by industry veterans, institutional venture and strategic investors.
SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Its first investigational product, Aurase, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds.
Dr Sam Bakri, founder and CEO of SolasCure, said: 鈥淲e are delighted to have completed our Series A round, which will help us to move onto the clinical trial stages of product development.聽聽
鈥淲e are excited to be working with such knowledgeable and specialist investors, as they join us on our mission to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.鈥�
/ai-drugs-firm-to-create-100-jobs/
The raise began with investment from BRAIN Biotech AG, its largest shareholder.
Adriaan Moelker, CEO at Germany-listed BRAIN Biotech, said: 鈥淚t has been an encouraging sign for all partners that SolasCure has been able to successfully close another financing round with rising pre-money valuation during the pandemic.聽
鈥淲e continue to be committed to support SolasCure on its way to market for the innovative wound debridement enzyme Aurase.鈥�
The round was completed following investment by Seneca Partners, an investment management business based in the UK.
Matt Currie, investment director at Seneca, said: 鈥淲e are delighted to support SolasCure as part of this latest funding round. The team they have brought together are truly world-class, producing ground-breaking work in the wound care sector.聽
鈥淧ractitioners are crying out for a high-quality solution that can be transported, stored and administered in an efficient and effective way, something severely lacking in the treatments available at present. We believe SolasCure鈥檚 Aurase product has the potential to become the go-to solution in this space.鈥�
Other notable investors to date include Bionova Capital, experienced entrepreneur and life sciences angel investor Jonathan Milner (founder of Abcam), strategic investor EVA Pharma, the Development Bank of Wales, as well as Fran莽ois Fournier (former lead of Smith & Nephew鈥檚 Advanced Wound Care division).